<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121455</url>
  </required_header>
  <id_info>
    <org_study_id>SNOXA12C401</org_study_id>
    <secondary_id>2018-004064-62</secondary_id>
    <nct_id>NCT04121455</nct_id>
  </id_info>
  <brief_title>Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients</brief_title>
  <acronym>GLORIA</acronym>
  <official_title>Single-arm Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a 2-arm Expansion Group Including Fully Resected Patients and Combination With Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NOXXON Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NOXXON Pharma AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain first, exploratory information on the safety and&#xD;
      efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly&#xD;
      diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection&#xD;
      (biopsy only) or after incomplete tumor resection, (ii) olaptesed pegol in combination with&#xD;
      radiation therapy and bevacizumab in patients with newly diagnosed glioblastoma of&#xD;
      unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after&#xD;
      incomplete tumor resection and (iii) olaptesed pegol in combination with radiation therapy in&#xD;
      patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status after&#xD;
      complete tumor resection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 dose escalation and a 2-arm expansion group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Number of patients with treatment-related adverse events as assessed by CTCAE</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of patients with treatment-related adverse events as assessed by CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - progression free survival at 6 months (PFS-6)</measure>
    <time_frame>6 months</time_frame>
    <description>Progression free survival at 6 months (PFS-6) in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Median progression-free survival (mPFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Median progression-free survival (mPFS) in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Median overall survival (mOS)</measure>
    <time_frame>24 months</time_frame>
    <description>Median overall survival (mOS) in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Tumor vascularization as per vascular MRI</measure>
    <time_frame>24 months</time_frame>
    <description>Changes from baseline in tumor vascularization over time as %cerebral blood volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of olaptesed pegol</measure>
    <time_frame>26 weeks</time_frame>
    <description>concentration of olaptesed pegol in plasma in µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) EORTC QLQ-C30 Module</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of Life measures are recorded according to EORTC QLQ30 module, which is validated for cancer patients in general and measured as a unit of scale. This is a standard tool for assessing patient reported quality of Life along time during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) EORTC QLQ BN-20 Module</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of Life measures are recorded according to EORTC QLQ BN-20 module, which is validated for brain tumor patients and measured as a unit of scale. This is a standard tool for assessing patient reported quality of Life along time during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic functions as measured by the NANO scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in neurologic performance scores by Neurologic Assessment in Neuro-Oncology (NANO) scale as an objective and quantifiable metric of neurologic function evaluable during a routine office examination. The NANO Scale evaluates 9 major domains of neurologic function, with each domain being scored on a range from 0 to 2 or 3.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 200 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 400 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: 600 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion group, Arm A: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, bevacizumab every two weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely or not resected patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion group, Arm B: 600 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6, completely resected patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaptesed pegol</intervention_name>
    <description>Olaptesed pegol continuous administration for 26 weeks</description>
    <arm_group_label>Cohort 1: 200 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_label>Cohort 2: 400 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_label>Cohort 3: 600 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_label>Expansion group, Arm A: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab</arm_group_label>
    <arm_group_label>Expansion group, Arm B: 600 mg Olaptesed pegol + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions</description>
    <arm_group_label>Cohort 1: 200 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_label>Cohort 2: 400 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_label>Cohort 3: 600 mg Olaptesed pegol + Radiotherapy</arm_group_label>
    <arm_group_label>Expansion group, Arm A: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab</arm_group_label>
    <arm_group_label>Expansion group, Arm B: 600 mg Olaptesed pegol + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab every 2 weeks i.v. for 26 weeks</description>
    <arm_group_label>Expansion group, Arm A: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab</arm_group_label>
    <other_name>MVASI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Dose Escalation Cohorts:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Patient agreement to diagnostic and scientific work-up of glioblastoma tissue obtained&#xD;
             during the preceding surgery or biopsy&#xD;
&#xD;
          4. Patient agrees to subcutaneous port implantation&#xD;
&#xD;
          5. Newly diagnosed, histologically confirmed, supratentorial WHO grade IV glioblastoma&#xD;
&#xD;
          6. Status post biopsy or incomplete resection&#xD;
&#xD;
          7. Unmethylated MGMT promoter status&#xD;
&#xD;
          8. Maximum Eastern Cooperative Oncology Group (ECOG) score 2&#xD;
&#xD;
          9. Estimated minimum life expectancy 3 months&#xD;
&#xD;
         10. Stable or decreasing dose of corticosteroids during the week prior to inclusion&#xD;
&#xD;
         11. The following laboratory parameters should be within the ranges specified:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit normal (ULN)&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x ULN or glomerular filtration rate ≥ 60 mL/min/1.73m²&#xD;
&#xD;
               -  ALT (alanine transaminase) ≤ 3 x ULN&#xD;
&#xD;
               -  AST (aspartate transaminase) ≤ 3 x ULN&#xD;
&#xD;
         12. Female patients of child-bearing potential must have a negative serum pregnancy test&#xD;
             within 21 days prior to enrollment and agree to use a highly effective method of birth&#xD;
             control (failure rate less than 1% per year when used consistently and correctly such&#xD;
             as contraceptive implants, vaginal rings, sterilization, or sexual abstinence)&quot; during&#xD;
             and for 3 months following last dose of drug (more frequent pregnancy tests may be&#xD;
             conducted if required per local regulations)&#xD;
&#xD;
         13. Male patients must use an effective barrier method of contraception during study and&#xD;
             for 3 months following the last dose if sexually active with a FCBP&#xD;
&#xD;
        Inclusion Criteria Expansion Group:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Patient agreement to diagnostic and scientific work-up of glioblastoma tissue obtained&#xD;
             during the preceding surgery or biopsy (e.g., MGMT promoter analysis, cytogenetic&#xD;
             markers such as IDH-1 mutations, etc.)&#xD;
&#xD;
          4. Patient agrees to subcutaneous port implantation&#xD;
&#xD;
          5. Newly diagnosed, histologically confirmed, supratentorial WHO grade IV glioblastoma&#xD;
&#xD;
          6. a) Status post biopsy or incomplete resection (detectable residual tumor as per&#xD;
             postoperative T1-weighted, contrast-enhanced MRI scan) (Arm A) OR b) Status post&#xD;
             complete resection (Arm B)&#xD;
&#xD;
          7. Unmethylated MGMT promoter status&#xD;
&#xD;
          8. Maximum Eastern Cooperative Oncology Group (ECOG) score 2&#xD;
&#xD;
          9. Estimated minimum life expectancy 3 months&#xD;
&#xD;
         10. Stable or decreasing dose of corticosteroids during the week prior to inclusion&#xD;
&#xD;
         11. The following laboratory parameters should be within the ranges specified:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit normal (ULN)&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x ULN or glomerular filtration rate ≥ 60 mL/min/1.73m²&#xD;
&#xD;
               -  ALT (alanine transaminase) ≤ 3 x ULN&#xD;
&#xD;
               -  AST (aspartate transaminase) ≤ 3 x ULN&#xD;
&#xD;
         12. Female patients of child-bearing potential must have a negative serum pregnancy test&#xD;
             within 21 days prior to enrollment and agree to use a highly effective method of birth&#xD;
             control (failure rate less than 1% per year when used consistently and correctly such&#xD;
             as contraceptive implants, vaginal rings, sterilization, or sexual abstinence) during&#xD;
             and for 3 months (6 months Arm A) following last dose of drug (more frequent pregnancy&#xD;
             tests may be conducted if required per local regulations)&#xD;
&#xD;
         13. Male patients must use an effective barrier method of contraception during study and&#xD;
             for 3 months (6 months Arm A) following the last dose if sexually active with a FCBP&#xD;
&#xD;
        Exclusion Criteria Dose Escalation Cohorts:&#xD;
&#xD;
          1. Inability to understand and collaborate throughout the study or inability or&#xD;
             unwillingness to comply with study requirements&#xD;
&#xD;
          2. Participation in any clinical research study with administration of an investigational&#xD;
             drug or therapy within 30 days from screening visit or observation period of competing&#xD;
             studies&#xD;
&#xD;
          3. Contra-indication or known hypersensitivity to MRI contrast agents, olaptesed pegol or&#xD;
             polyethylene glycol&#xD;
&#xD;
          4. Cytostatic therapy (chemotherapy) within the past 5 years&#xD;
&#xD;
          5. History of other cancers (except for adequately treated basal or squamous cell skin&#xD;
             cancer, in situ cervical cancer, or other cancer from which the patient was&#xD;
             disease-free for ≥ 5 years)&#xD;
&#xD;
          6. Clinically significant or uncontrolled cardiovascular disease&#xD;
&#xD;
          7. Prior radiotherapy to the head&#xD;
&#xD;
          8. Any other previous or concomitant experimental glioblastoma treatments&#xD;
&#xD;
          9. Placement of Gliadel® wafer, seeds, or ferromagnetic nanoparticles&#xD;
&#xD;
         10. Pregnancy or lactation&#xD;
&#xD;
         11. Uncontrolled intercurrent illness; patients must be free of any clinically relevant&#xD;
             disease (other than glioma) that would, in the treating investigator's opinion,&#xD;
             interfere with the conduct of the study or study evaluations&#xD;
&#xD;
         12. Treatment not initiated within 6 weeks after first biopsy or surgery of glioblastoma&#xD;
&#xD;
         13. Prior enrolment into this study&#xD;
&#xD;
        Exclusion Criteria Expansion Group:&#xD;
&#xD;
          1. Inability to understand and collaborate throughout the study or inability or&#xD;
             unwillingness to comply with study requirements&#xD;
&#xD;
          2. Participation in any clinical research study with administration of an investigational&#xD;
             drug or therapy within 30 days from screening visit or observation period of competing&#xD;
             studies&#xD;
&#xD;
          3. Contra-indication or known hypersensitivity to MRI contrast agents, bevacizumab (Arm A&#xD;
             only) olaptesed pegol or polyethylene glycol&#xD;
&#xD;
          4. Planned hypofractionated radiotherapy&#xD;
&#xD;
          5. Cytostatic therapy (chemotherapy) within the past 5 years&#xD;
&#xD;
          6. History of other cancers (except for adequately treated basal or squamous cell skin&#xD;
             cancer, in situ cervical cancer, or other cancer from which the patient was&#xD;
             disease-free for ≥ 5 years)&#xD;
&#xD;
          7. Secondary malignancy which is currently active&#xD;
&#xD;
          8. Clinically significant or uncontrolled cardiovascular disease, including&#xD;
&#xD;
               -  Myocardial infarction in the previous 12 months&#xD;
&#xD;
               -  Uncontrolled angina&#xD;
&#xD;
               -  Congestive heart failure (New York Heart Association functional classification of&#xD;
                  ≥2)&#xD;
&#xD;
               -  Diagnosed or suspected congenital long QT syndrome&#xD;
&#xD;
               -  QTc prolongation on an electrocardiogram prior to entry (&gt;470 ms)&#xD;
&#xD;
               -  Uncontrolled hypertension (blood pressure ≥ 160/95 mmHg)&#xD;
&#xD;
               -  Heart rate &lt;50/min on the baseline electrocardiogram&#xD;
&#xD;
               -  History of ventricular arrhythmias of any clinically significant type (such as&#xD;
                  ventricular tachycardia, ventricular fibrillation or torsades de pointes)&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
          9. Prior radiotherapy to the head&#xD;
&#xD;
         10. Any other previous or concomitant experimental glioblastoma treatments&#xD;
&#xD;
         11. Placement of Gliadel® wafer, seeds, or ferromagnetic nanoparticles&#xD;
&#xD;
         12. Patients with a history of arterial or venous thrombosis (or any other disease)&#xD;
             requiring permanent intake of anticoagulants (Arm A only)&#xD;
&#xD;
         13. Pregnancy or lactation&#xD;
&#xD;
         14. Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, chronic liver disease (e.g., cirrhosis, hepatitis), diabetes mellitus, or&#xD;
             subjects with either of the following: fasting blood glucose (FBG defined as fasting&#xD;
             for at least 8 hours) ≥ 200 mg/dL (7.0 mmol/L), or HbA1c ≥ 8%, chronic renal disease,&#xD;
             pancreatitis, chronic pulmonary disease, auto-immune diseases, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
             Patients must be free of any clinically relevant disease (other than glioma) that&#xD;
             would, in the treating investigator's opinion, interfere with the conduct of the study&#xD;
             or study evaluations&#xD;
&#xD;
         15. Prolongation of coagulation factors ≥ 2.5 x ULN (Arm A only)&#xD;
&#xD;
         16. Treatment not initiated within 6 weeks after first biopsy or surgery of glioblastoma&#xD;
&#xD;
         17. Prior enrolment into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diana Beyer, Dr.</last_name>
    <phone>+49 30 72 62 47</phone>
    <phone_ext>100</phone_ext>
    <email>clinicaltrialdisclosuredesk@noxxon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie Schwerpunkt Klinische Neuroonkologie</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie mit Institut für Translationale Neurologie</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abteilung Neurologie mit interdisziplinärem Schwerpunkt Neuroonkologie</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>NOX-A12</keyword>
  <keyword>Olaptesed pegol</keyword>
  <keyword>Spiegelmer</keyword>
  <keyword>Stromal cell-derived factor-1 (SDF-1)</keyword>
  <keyword>CXCL12</keyword>
  <keyword>Radiation</keyword>
  <keyword>MGMT promoter</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Brain cancer</keyword>
  <keyword>Tumor microenvironment</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

